Prescription rates increased from 2021 to 2023, but high variance seen between hospitals in the rate of prescriptions ...

AXS-12 is an investigational highly selective potent norepinephrine reuptake inhibitor and cortical dopamine modulator.

The approval was based on data from 5 randomized, double-blind, placebo-controlled trials that included 317 patients with supraventricular tachycardia.

Vaccination of 'mid-adults,' including those at higher risk, results in higher number needed to vaccinate than that seen for younger people ...